|
Powered by Cell Signaling Technology |
Site Information |
---|
RGAMsVDsItDLDDN SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 14569891 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Treatments: |
References | |
---|---|
Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32
28852199 Curated Info |
|
Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371
20531401 Curated Info |
|
Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140 Curated Info |